Valuation: Moderna, Inc.

Market Cap 85.33B 76.39B 71.21B 64.59B 122B 8,157B 123B 856B 335B 4,209B 321B 313B 13,546B P/E 2026 *
-25.5x
P/E 2027 * -44.7x
Enterprise Value 81.42B 72.89B 67.95B 61.63B 116B 7,783B 117B 817B 320B 4,016B 306B 299B 12,925B EV / Sales 2026 *
38.7x
EV / Sales 2027 * 34x
Free-Float
92.66%
Yield 2026 *
-
Yield 2027 * -
1 day-2.99%
1 week+5.18%
Current month+10.99%
1 month+48.46%
3 months+213.08%
6 months+319.43%
Current year+624.79%
1 week 182.5
Extreme 182.5
227.46
1 month 139.02
Extreme 139.02
227.46
Current year 29.81
Extreme 29.81
227.46
1 year 22.28
Extreme 22.28
227.46
3 years 22.28
Extreme 22.28
227.46
5 years 22.28
Extreme 22.28
376.65
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 A Other

Chief Operating Officer

125,000 0.0313%
10/5/26 A Exercice

Chief Financial Officer

3,612 0.0009%
9/15/26 A Exercice

Chairperson

193,185 0.0484%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%+5.18%+696.65%+112.09% 85.33B
+0.28%+3.46%+41.89%+93.71% 1,054B
+0.88%+4.27%+38.28%+68.70% 636B
+1.68%+5.78%+21.96%+89.56% 497B
-0.10%+4.24%+69.15%+40.41% 359B
+1.04%+3.97%+25.37%+42.60% 345B
+0.83%+3.23%+15.75%+38.21% 273B
+1.19%+1.74%-4.39%+10.86% 246B
+0.65%+3.62%+43.93%+46.50% 226B
-0.49%+4.01%+28.38%+95.97% 187B
Average +0.16%+3.35%+97.70%+63.86% 390.75B
Weighted average by Cap. +0.24%+3.24%+48.84%+68.38%

Financials

2026 *2027 *
Net sales 2.1B 1.88B 1.75B 1.59B 3B 201B 3.02B 21.07B 8.25B 104B 7.89B 7.72B 334B 2.44B 2.18B 2.04B 1.85B 3.48B 233B 3.5B 24.46B 9.57B 120B 9.16B 8.96B 387B
Net income -3.36B -3.01B -2.8B -2.54B -4.79B -321B -4.82B -33.68B -13.18B -166B -12.62B -12.34B -533B -1.92B -1.71B -1.6B -1.45B -2.73B -183B -2.75B -19.21B -7.52B -94.47B -7.19B -7.03B -304B
Net Debt -3.91B -3.5B -3.27B -2.96B -5.59B -374B -5.62B -39.24B -15.36B -193B -14.7B -14.37B -621B -2.44B -2.19B -2.04B -1.85B -3.49B -234B -3.51B -24.51B -9.6B -121B -9.18B -8.98B -388B
Projected Income Statement - Annual - Moderna, Inc.
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
12/10/26 $213.74 -5.00% 12,873,864
09/10/26 $225.00 +14.21% 28,947,262
08/10/26 $197.00 +0.26% 37,399,978
07/10/26 $196.48 +4.81% 14,640,181
06/10/26 $187.46 -7.75% 18,794,807
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Moderna, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
213.74USD
Average target price
122.67USD
Spread / Average Target
-42.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Moderna, Inc.
  1. Stock Market
  2. Stocks
  3. MRNA Stock